Morphometric studies on wound healing after systemic administration of adriamycin and local application of fibrin sealant. Application of a new wound healing model using spongiosa implants.
For investigations on the development of regenerative granulation tissue in wound healing a new model using bone spongiosa ("Kieler Spongiosa") implants is presented. Particular attention was devoted to developing a model which permits studies on wound healing without disturbance by foreign body reaction and infections. Two test groups of rats received four blocks of "Kieler Spongiosa" each in a symmetrical fashion in a paramedian region underneath the dorsal skin. The spongiosa blocks had previously been treated with glutaraldehyde to achieve cross-linkage of the collagenous structures of the surfaces of the spongiosa trabeculae. After one week (group 1) and two weeks (group 2) the animals were sacrificed. The spongiosa blocks were removed, fixed and evaluated in layered serial sections after decalcification. Two blocks which had been removed randomly from the back and front served for morphometric determination of the total volume of bony substance and the developed granulation tissue. Moreover, the cellular composition of the granulation tissue was morphometrically examined with regard to its content of capillaries, granulation tissue cells and inflammatory cells. The two other blocks were examined for DNA and hydroxyproline content of granulation tissue. Comparison of the two experimental groups yielded marked differences in spongiosa space infiltrated by granulation tissue and its composition. Our model was used to assess the influence of systemic administration of adriamycin and/or local application of a fibrin sealant system on granulation tissue formation and its morphologic structure.(ABSTRACT TRUNCATED AT 250 WORDS)
D000818:Animals; D007611:Aprotinin / Q000494:pharmacology*; D004247:DNA / Q000378:metabolism; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000494:pharmacology*; D004338:Drug Combinations / Q000494:pharmacology; D005176:Factor XIII / Q000494:pharmacology*; D015718:Fibrin Tissue Adhesive; D005340:Fibrinogen / Q000494:pharmacology*; D006097:Granulation Tissue / Q000033:anatomy & histology / Q000378:metabolism; D006909:Hydroxyproline / Q000378:metabolism; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D013917:Thrombin / Q000494:pharmacology*; D014945:Wound Healing / Q000187:drug effects*
D004338:Drug Combinations; D015718:Fibrin Tissue Adhesive; D004317:Doxorubicin; D005340:Fibrinogen; D004247:DNA; D005176:Factor XIII; D007611:Aprotinin; D013917:Thrombin; D006909:Hydroxyproline